Intranasal Peptide Delivery: Bioavailability, Factors & Comparison with Injectables

Peptides generally have poor oral bioavailability (<2%) due to gastrointestinal enzymatic degradation and low intestinal permeability. Subcutaneous injection bypasses these barriers but requires needles, sterile technique, and reconstitution — creating compliance barriers. The nasal mucosa offers a richly vascularized, permeable epithelium with a large surface area (~150 cm²), enabling non-invasive systemic and CNS delivery.

Peptides deposited on the nasal epithelium can be absorbed via two primary pathways: (1) Systemic absorption — peptides cross the nasal epithelium into capillaries, entering systemic circulation. This pathway is relevant for peripherally acting peptides like Desmopressin and GLP-1 analogues. (2) Nose-to-brain (N2B) — peptides travel along olfactory and trigeminal nerve pathways directly to the CNS, bypassing the blood-brain barrier. This is particularly relevant for neuropeptides like Semax, Selank, and Oxytocin.

Subcutaneous injection provides near-100% bioavailability. Intranasal bioavailability varies significantly by peptide: Desmopressin (DDAVP) achieves 3-5% nasal bioavailability — but this is sufficient for clinical efficacy at adjusted doses (FDA-approved as Stimate® nasal spray). Oxytocin nasal spray (Syntocinon®) achieves approximately 2-5% systemic bioavailability but demonstrates measurable CNS effects, suggesting significant nose-to-brain transport. Semax achieves reported bioavailability of 6-12% intranasally, with rapid brain penetration. Calcitonin (Miacalcin®) achieves ~3% nasal bioavailability — sufficient for FDA-approved osteoporosis treatment. Larger peptides (>6 kDa) generally have <1% nasal bioavailability without absorption enhancers.

Five key factors determine intranasal peptide absorption: (1) Molecular weight — peptides <1 kDa cross the nasal epithelium relatively well; those >6 kDa require enhancers. (2) Lipophilicity — more lipophilic peptides show better transcellular absorption. (3) Mucociliary clearance — the nasal mucosa clears deposited material within 12-15 minutes, limiting absorption time. (4) Formulation — absorption enhancers (cyclodextrins, chitosan, bile salts), mucoadhesive polymers, and proper pH (4.5-6.5) can dramatically improve bioavailability. (5) Delivery volume — optimal per-nostril volume is 100-150 μL; larger volumes drain to the pharynx and are swallowed.

Non-invasive (no needles, no reconstitution), rapid absorption (Tmax typically 10-30 minutes), direct CNS access bypassing the blood-brain barrier, avoidance of first-pass hepatic metabolism, improved patient compliance and self-administration ease, portability and convenience. For neuropeptides specifically targeting the brain (Semax, Selank, Oxytocin), intranasal delivery may actually be superior to injection for CNS targeting.

Lower systemic bioavailability (2-30% vs ~100% for SubQ), variable absorption between individuals, limited dose volume per nostril (100-150 μL), mucociliary clearance reduces contact time, nasal congestion or rhinitis can significantly impair absorption, enzymatic degradation by nasal proteases, potential local irritation with long-term use, lack of standardized formulations for many research peptides.

Several peptides have regulatory-approved intranasal formulations, validating the route: Desmopressin (Stimate®, DDAVP Nasal) for diabetes insipidus and bleeding disorders. Calcitonin (Miacalcin®, Fortical®) for osteoporosis. Oxytocin (Syntocinon®) for lactation support. Nafarelin (Synarel®) for endometriosis and precocious puberty. These approvals demonstrate that despite lower bioavailability, therapeutic efficacy is achievable with dose adjustment.

Several research peptides are studied via intranasal delivery: Semax — extensively studied in Russia for cognitive enhancement and neuroprotection. Selank — anxiolytic/nootropic peptide studied intranasally. BPC-157 — emerging research on nasal delivery for systemic and CNS effects. PT-141 (Bremelanotide) — studied intranasally before the SubQ formulation was FDA-approved. Exendin-4 — GLP-1 analogue studied intranasally as an alternative to injection. These remain investigational with varying levels of evidence.

Modern nasal formulations use various enhancers to improve peptide absorption: Cyclodextrins (especially hydroxypropyl-β-CD) — increase solubility and permeation. Chitosan — mucoadhesive polymer that opens tight junctions and extends contact time. Bile salt derivatives (sodium glycocholate) — permeation enhancers used in some approved products. Polyethylene glycol (PEG) — stabilizer and co-solvent. pH buffering — maintaining 4.5-6.5 for optimal stability and minimal irritation. These enhancers can increase nasal bioavailability 2-10 fold.

When evaluating intranasal vs injectable delivery for research purposes, consider: the target tissue (CNS vs peripheral), required systemic exposure level, peptide molecular weight and stability, dose-response relationship, and whether an approved nasal formulation exists as a reference. AllPeptides.eu maintains educational protocols for both injectable and nasal spray peptides with appropriate evidence-level designations.

For detailed dosing, storage and administration information, see our dedicated guides: Semax Spray — nootropic/neuroprotective, approved in Russia. Selank Spray — anxiolytic neuropeptide. Oxytocin Spray — social cognition, hundreds of studies. BPC-157 Spray — investigational, emerging data. Desmopressin Spray — FDA-approved (Stimate®). Exendin-4 Spray — GLP-1 analogue. Leptin Spray — investigational. PT-141 Spray — discontinued nasal development (historical). TB-500 Spray — investigational, neuroprotection research.